All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-09-23T09:28:09.000Z

How has AML treatment in elderly people changed in 2021?

By Mark Maitland
Featured
Tapan M. Kadia
Sep 23, 2021
Share:

Bookmark this article

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Tapan M. Kadia, MD Anderson Cancer Center, Houston, US. We asked, How has acute myeloid leukemia treatment in elderly people changed in 2021?

How has AML treatment in elderly people changed in 2021?

Kadia begins by highlighting the treatment challenges for elderly patients, such as higher frequency of comorbidities, organ dysfunction, and frailty. He outlines therapies such as venetoclax and hypomethylating agents, which demonstrate a good safety profile. Finally, he discusses current studies that are further investigating the role of NGS and cytogenetic analysis in selecting treatment options and therapy combinations.

 

More about...
Hypomethylating agentsRiskSOHO 2021Venetoclax

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 2 days left ...

Related articles

Add bookmark

Venetoclax plus decitabine vs intensive chemotherapy for young patients with ND AML

Here, we summarize a presentation by Jing Lu from ASH 2023 comparing the safety and efficacy of venetoclax plus decitabine vs intensive chemotherapy in newly...

Feb 29, 2024
Add bookmark

Venetoclax plus decitabine vs intensive chemotherapy for young patients with ND AML

Here, we summarize a presentation by Jing Lu from ASH 2023 comparing the safety and efficacy of venetoclax plus...

Feb 29, 2024
Add bookmark

Survival outcomes in older patients receiving CPX-351 versus HMA + venetoclax as frontline AML therapy

New frontline therapy options have recently improved the acute myeloid leukemia (AML) treatment landscape for older patients, including the...

Jan 26, 2022
Add bookmark

Survival outcomes in older patients receiving CPX-351 versus HMA + venetoclax as frontline AML therapy

New frontline therapy options have recently improved the acute myeloid leukemia (AML) treatment...

Jan 26, 2022

Newsletter

Subscribe to get the best content related to AML delivered to your inbox